The changing face of hypertension treatment: Treatment strategies from the 2007 ESH/ESC hypertension Guidelines

Journal of Hypertension

Volumn 27, Issue SUPPL. 3, 2009, Pages

  Williams, Bryan ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Antihypertensive; Blood pressure; Clinical guidelines; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; DRUG COMBINATION; EUROPE; LIFESTYLE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; HYPERTENSION; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC;

EID: 69149101226     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000356768.24507.69     Document Type: Review

References (27)

1. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/ International Society of Hypertension meeting. J Hypertens 1993; 11:905-918.
2. Top 10 papers published. The Scientist 2005; 19:26.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762. (Pubitemid 47356612)
4. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook SW, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomised controlled trials. J Hypertens 2006; 24:215-233.
5. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47:296-308.
6. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288:2880-2883.
7. Williams B. Recent Hypertension Trials. Implications and controversies. J Am Coll Cardiol 2005; 45:813-827.
8. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
9. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-1076.
10. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419.
11. Williams B. Hypertension in the young-preventing the evolution of disease versus prevention of clinical events. J Am Coll Cardiol 2007; 50:840-842.
12. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005; 23:1777-1781.
13. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
14. Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, et al., ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008; 118:2259-2267.
15. Williams B. Beta-blockers and the treatment of hypertension. J Hypertens 2007; 25:1351-1353.
16. Lindholm LH, Carlberg B, Samuelsson O. Should b blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
17. Wiysonge CSU, Bradley HA, Mayosi BM, Maroney RT, Mbewu A, Opie L, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; 1:CD002003.
18. Williams B. The obese hypertensive: the weight of evidence against beta-blockers. Circulation 2007; 115:1973-1974.
19. NICE/BHS. Clinical guideline 34: hypertension: management of hypertension in adults in primary care: partial update. Available at: http://www.nice.org. uk/CG034guidance. Accessed: 28 December 2008.
20. Higgens B, Williams B, for the Guideline Development Group. Pharmacological management of hypertension. Clin Med 2007; 7:612-616.
21. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368:1449-1456; [Erratum in Lancet 2006; 368:2124].
22. ALLHAT Investigators. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1967-1975. [Erratum in JAMA 2002; 288:2976].
23. ChapmanN,Chang CL, DahlöfB,Sever PS, WedelH, Poulter NR, ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118:42-48.
24. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25:891-894.
25. Chapman N, Dobson J, Wilson S, et al., on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845.
26. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., ON-TARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
27. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.